Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2023 Filed Jan 12, 2023 02:01 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 85,102 | $11.43 | $972,954.15 |
DisclosureSEC source: 0001209191-23-003083 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,229 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.24 to $11.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:04 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 10,659 | $12.03 | $128,227.77 |
DisclosureSEC source: 0001209191-23-002395 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,331 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 414,025 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001209191-23-001400 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,025 Underlying: Common Stock · 414,025 shares Expires 2033-01-03 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 233,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001400 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980,990 F1 · shares: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 00:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 22,116 | $11.93 | $263,843.88 |
DisclosureSEC source: 0001209191-23-001400 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,742 Read SEC document |
| January 02, 2023 Filed Jan 5, 2023 00:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 21,596 | $12.21 | $263,687.16 |
DisclosureSEC source: 0001209191-23-001400 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,858 Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 23:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $12.15 | $127,171.54 |
DisclosureSEC source: 0001209191-22-062014 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,454 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.96 to $12.34 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,347 | $12.20 | $138,473.11 |
DisclosureSEC source: 0001209191-22-059829 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,922 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.98 to $12.31 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $11.64 | $121,866.36 |
DisclosureSEC source: 0001209191-22-057594 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.45 to $11.79 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 00:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $10.32 | $117,052.14 |
DisclosureSEC source: 0001209191-22-055675 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,737 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.90 to $10.47 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 22:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $10.90 | $114,148.31 |
DisclosureSEC source: 0001209191-22-054130 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,083 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.66 to $11.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $10.75 | $121,926.39 |
DisclosureSEC source: 0001209191-22-052856 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,551 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.46 to $10.99 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:56 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $10.66 | $111,627.61 |
DisclosureSEC source: 0001062993-22-019752 · form4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,897 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.22 to $10.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 21:04 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $11.30 | $128,162.15 |
DisclosureSEC source: 0001209191-22-048794 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.96 to $11.57 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:23 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $12.28 | $128,584.72 |
DisclosureSEC source: 0001209191-22-046399 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,711 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.12 to $12.42 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2022 Filed Aug 4, 2022 00:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $9.96 | $113,028.85 |
DisclosureSEC source: 0001209191-22-044343 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,179 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.75 to $10.23 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 21:02 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $10.86 | $113,674.11 |
DisclosureSEC source: 0001209191-22-042597 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.73 to $11.04 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 00:20 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $10.78 | $122,337.11 |
DisclosureSEC source: 0001209191-22-041399 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,993 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.57 to $10.97 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 10,468 | $8.01 | $83,839.26 |
DisclosureSEC source: 0001209191-22-038009 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,339 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.05 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037592 · doc4.xml · derivative · entry 2 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037592 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 22:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 11,346 | $8.00 | $90,768.00 |
DisclosureSEC source: 0001209191-22-034894 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 11,918 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001104659-22-068501 · tm2217670-2_4seq1.xml · derivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 Underlying: Common Stock · 11,918 shares Expires 2032-06-02 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:18 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 21,814 | $8.00 | $174,566.54 |
DisclosureSEC source: 0001209191-22-031930 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944,153 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.02 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 21:39 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 8,254 | $8.01 | $66,082.35 |
DisclosureSEC source: 0001209191-22-025052 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,967 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 21:39 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 2,214 | $8.04 | $17,794.14 |
DisclosureSEC source: 0001209191-22-025052 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,221 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.15 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 23:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 8,564 | $10.23 | $87,609.72 |
DisclosureSEC source: 0001209191-22-003820 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,435 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 438,222 | $0.00 Strike: $12.11 | $0.00 |
DisclosureSEC source: 0001209191-22-003820 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,222 Underlying: Common Stock · 438,222 shares Expires 2032-01-14 F5 · derivative.exercise_date: These options vest and become exercisable in a series of installments over a four year period, with 25% vesting on January 3, 2023 and the remaining 75% vesting ratably each month thereafter. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 58,891 | $10.53 | $620,122.23 |
DisclosureSEC source: 0001209191-22-003820 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 984,999 Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 149,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003820 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,890 F3 · price: Granted for the achievement of the 2019 PRSU TSR goal as determined by the Board of Directors. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 239,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003820 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,230 F1 · shares: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. F2 · price: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 00:53 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | PurchaseCommon Stock | 5,000 | $9.72 | $48,575.00 |
DisclosureSEC source: 0001104659-22-004129 · tm222967-1_4seq1.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:20 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 63,543 | $12.18 | $774,118.95 |
DisclosureSEC source: 0001209191-22-002472 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,131 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Comprised of 46,910 shares received from the 2019 PRSU grant, awarded for exceeding the Galafold revenue goal for the applicable measurement period, and 16,333 shares received from the 2018 annual grant, the receipt of which were deferred by Mr. Crowley until January 1, 2022. F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.95 to $12.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 02:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 11,336 | $12.48 | $141,473.28 |
DisclosureSEC source: 0001209191-22-001221 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,674 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 40,069 | $12.11 | $485,235.59 |
DisclosureSEC source: 0001209191-22-001221 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,010 Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 02:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 22,968 | $11.55 | $265,280.40 |
DisclosureSEC source: 0001209191-22-001221 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,079 Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 31,479 | $11.55 | $363,582.45 |
DisclosureSEC source: 0001209191-22-001221 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,047 Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 24,935 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-065296 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,935 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 24,935 | $11.75 | $292,951.34 |
DisclosureSEC source: 0001209191-21-065296 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,526 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 24,935 | $4.38 | $109,215.30 |
DisclosureSEC source: 0001209191-21-065296 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 27,739 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-21-062794 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,739 shares Expires 2024-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 27,739 | $12.00 | $332,868.00 |
DisclosureSEC source: 0001209191-21-062794 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,526 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 27,739 | $3.82 | $105,962.98 |
DisclosureSEC source: 0001209191-21-062794 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,819 | $10.80 | $84,450.67 |
DisclosureSEC source: 0001209191-21-062794 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,526 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.45 to $10.94 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 22:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 11,918 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-132474 · tm2131250-16_4seq1.xml · derivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 Underlying: Common stock · 11,918 shares Expires 2031-10-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of October 28, 2021 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 01:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-060811 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,935 Underlying: Common Stock · 22,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 01:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,000 | $11.22 | $246,870.80 |
DisclosureSEC source: 0001209191-21-060811 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.09 to $11.52 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 01:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $4.38 | $96,360.00 |
DisclosureSEC source: 0001209191-21-060811 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 20:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $18.83 | $0.00 |
DisclosureSEC source: 0001209191-21-060359 · doc4.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 2,500 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 12,666 shares as of October 11, 2021. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 20:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,500 | $119.55 | $298,875.00 |
DisclosureSEC source: 0001209191-21-060359 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.